{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001020","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.655721+00:00","generated_at":"2026-05-26T06:39:25.370885+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst Q4 ORLADEYO rev $124.2M (+36.6%); FY2025 guidance raised; faces generic challenge","bullets":["Q4 ORLADEYO net revenue $124.2M (+36.6% YoY); full year 2024 net revenue $437.7M (+34.3% YoY).","FY 2024 GAAP operating loss $2.5M; non-GAAP operating profit $62.9M (excl. stock-based comp).","FY 2025 ORLADEYO revenue guidance raised to $535-550M from $515-535M; expects positive EPS in 2H 2025.","Annora Pharma filed ANDA for generic ORLADEYO; company intends to vigorously defend three patents expiring 2039.","NDA submission in 2025 for pediatric ORLADEYO granule (ages 2-11); initial data from BCX17725 and avoralstat expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001020","json":"https://secwatch.observer/filing/0001171843-25-001020.json","markdown":"https://secwatch.observer/filing/0001171843-25-001020.md","text":"https://secwatch.observer/filing/0001171843-25-001020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/0001171843-25-001020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/f8k_022425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:39:25.370885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}